69 related articles for article (PubMed ID: 19420948)
1. Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes.
Schaub M; Subata E; Chtenguelov V; Weiler G; Uchtenhagen A
Eur Addict Res; 2009; 15(3):157-62. PubMed ID: 19420948
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
Schaub M; Chtenguelov V; Subata E; Weiler G; Uchtenhagen A
Int J Drug Policy; 2010 May; 21(3):229-33. PubMed ID: 19926271
[TBL] [Abstract][Full Text] [Related]
3. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
Fhima A; Henrion R; Lowenstein W; Charpak Y
Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
[TBL] [Abstract][Full Text] [Related]
4. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)].
Duburcq A; Charpak Y; Blin P; Madec L
Rev Epidemiol Sante Publique; 2000 Aug; 48(4):363-73. PubMed ID: 11011303
[TBL] [Abstract][Full Text] [Related]
5. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
[TBL] [Abstract][Full Text] [Related]
6. Key findings from the WHO collaborative study on substitution therapy for opioid dependence and HIV/AIDS.
Lawrinson P; Ali R; Buavirat A; Chiamwongpaet S; Dvoryak S; Habrat B; Jie S; Mardiati R; Mokri A; Moskalewicz J; Newcombe D; Poznyak V; Subata E; Uchtenhagen A; Utami DS; Vial R; Zhao C
Addiction; 2008 Sep; 103(9):1484-92. PubMed ID: 18636999
[TBL] [Abstract][Full Text] [Related]
7. Comparison of high dose buprenorphine treatments of opiate dependent outpatients in four healthcare networks.
De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
Ann Med Interne (Paris); 2000 Oct; 151 Suppl B():B9-15. PubMed ID: 11104938
[TBL] [Abstract][Full Text] [Related]
8. Economic and social effects of high-dose buprenorphine substitution therapy. Six-month results.
Lavignasse P; Lowenstein W; Batel P; Constant MV; Jourdain JJ; Kopp P; Reynaud-Maurupt C; Riff B; Videau B; Mucchielli A
Ann Med Interne (Paris); 2002 May; 153(3 Suppl):1S20-6. PubMed ID: 12218879
[TBL] [Abstract][Full Text] [Related]
9. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
10. [Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians].
De Ducla M; Gagnon A; Mucchielli A; Robinet S; Vellay A
Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A27-32. PubMed ID: 10855374
[TBL] [Abstract][Full Text] [Related]
11. Opioid addicts at admission vs. slow-release oral morphine, methadone, and sublingual buprenorphine maintenance treatment participants.
Giacomuzzi S; Kemmler G; Ertl M; Riemer Y
Subst Use Misuse; 2006; 41(2):223-44. PubMed ID: 16393744
[TBL] [Abstract][Full Text] [Related]
12. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
Spire B; Lucas GM; Carrieri MP
Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
[TBL] [Abstract][Full Text] [Related]
13. [Buprenorphine abuse: high dose intravenous administration of buprenorphine].
Varescon I; Vidal-Trécan G; Nabet N; Boissonnas A
Encephale; 2002; 28(5 Pt 1):397-402. PubMed ID: 12386540
[TBL] [Abstract][Full Text] [Related]
14. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
Bruce RD; Dvoryak S; Sylla L; Altice FL
Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
Soeffing JM; Martin LD; Fingerhood MI; Jasinski DR; Rastegar DA
J Subst Abuse Treat; 2009 Dec; 37(4):426-30. PubMed ID: 19553061
[TBL] [Abstract][Full Text] [Related]
16. Abstinence-orientated buprenorphine replacement therapy for young adults in out-patient counselling.
Kornør H; Waal H; Ali RL
Drug Alcohol Rev; 2006 Mar; 25(2):123-30. PubMed ID: 16627301
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic response in outpatient opioid substitution treatment].
Barisić V; Barisić Z
Acta Med Croatica; 2009 Oct; 63(4):279-83. PubMed ID: 20034328
[TBL] [Abstract][Full Text] [Related]
18. [Outcome of a substitution therapy program in an outpatient treatment setting of a psychiatric hospital].
Unglaub W; Loncarek E; Wismath M; Johann M; Wodarz N; Klein H
Psychiatr Prax; 2004 Nov; 31 Suppl 1():S26-8. PubMed ID: 15570492
[TBL] [Abstract][Full Text] [Related]
19. Comparative treatment and mortality correlates and adverse event profile of implant naltrexone and sublingual buprenorphine.
Reece AS
J Subst Abuse Treat; 2009 Oct; 37(3):256-65. PubMed ID: 19394789
[TBL] [Abstract][Full Text] [Related]
20. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.
Lavie E; Fatséas M; Denis C; Auriacombe M
Drug Alcohol Depend; 2009 Jan; 99(1-3):338-44. PubMed ID: 18824311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
